Résumé
MS14 is a natural herbal-marine drug, which has shown to slow down or halt the progression of multiple sclerosis (MS). This drug consists of 90% Penaeus latisculatus, 5% Apium graveolens, and 5% Hypericum perforatum L. Preclinically, the effects of MS14 have mostly been examined in an animal model of multiple sclerosis called experimental allergic encephalomyelitis (EAE). Clinical studies of the effects of MS14 in MS patients also showed that it could improve the patients' quality of life. MS14 is a safe drug in MS patients and might also be effective in the treatment of other neurodegenerative disorders with the same mechanisms.
Sujets)
Animaux , Humains , Souris , Anti-inflammatoires , Utilisations thérapeutiques , Antioxydants , Utilisations thérapeutiques , Relation dose-effet des médicaments , Science des plantes médicinales , Iran , Médecine traditionnelle , Sclérose en plaques , Traitement médicamenteux , Extraits de plantes , Utilisations thérapeutiques , Eau de mer , Chimie , Extraits tissulaires , Utilisations thérapeutiquesRésumé
HESA-A, which contains biologically active compounds of marine origin, has selective toxicity against cancer cells. The present work reports the results of studies investigating the acute and sub-acute oral toxicity of this drug in mice and rats. In acute toxicity study, doses of HESA-A up to 13.7 g/kg and in sub-acute study, oral doses of 1250, 2500 and 5000 mg/kg for 30 consecutive days did not cause any morbidity or mortality. Data analysis of body weight gain, gross observations, blood biochemistry, hematology and histopathological findings did not show significant differences between control and treated groups. An oral dose of 5000 mg/kg of HESA-A can be defined as no-observed-adverse-effectlevel [NOAEL] for mice and rats used under the experimental conditions